Daprodustat

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth. The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions. Daprodustat was approved for medical use in Japan in June 2020, and in the United States in February 2023. making it the first oral treatment for anemia caused by chronic kidney disease for adults in the US. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth. The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions. Daprodustat was approved for medical use in Japan in June 2020, and in the United States in February 2023. making it the first oral treatment for anemia caused by chronic kidney disease for adults in the US. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. The efficacy and safety of daprodustat were evaluated in 2,964 adults with anemia due to chronic kidney disease on dialysis and receiving an erythropoiesis-stimulating agent at the time of study entry in a randomized, sponsor-blind, active-controlled, global, multicenter, event-driven clinical trial (ASCEND-D; NCT02879305). Participants were stratified by dialysis type and were required to be on dialysis for at least four months prior to the first dose of daprodustat. Participants on hemodialysis were randomized 1:1 to receive oral daprodustat (N=1,316) or intravenous epoetin alfa (N=1,308) while participants on peritoneal dialysis were randomized 1:1 to receive oral daprodustat (N=171) or subcutaneous darbepoetin alfa (N=169). In this study, adults received either oral daprodustat or injected recombinant human erythropoietin ( ) (a standard of care treatment for people with anemia due to chronic kidney disease). Daprodustat raised and maintained the hemoglobin (the protein in red blood cells that carries oxygen and is a common measure of anemia) within the target range of 10 to 11 g/dL, similar to that of the treatment. The trial was conducted at 431 sites in 35 countries. The FDA granted the approval of Jesduvroq to GlaxoSmithKline LLC.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1365572082 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.